Categories: News

Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update

SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2021 and provide a corporate update at 4:30 p.m. ET on February 28, 2022.

The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 5169343. A live webcast of the call will be available online in the investor relations section of Otonomy’s website at www.otonomy.com and will be archived there for 30 days.

About Otonomy

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs with a focus on hearing loss and tinnitus. For additional information, please visit www.otonomy.com.

Contacts:

Media Inquiries:
Spectrum Science
Cate Cullen
Account Director
205.910.4443
ccullen@spectrumscience.com

Investor Inquiries:
Westwicke ICR
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com

Staff

Recent Posts

10x Genomics to Present at the 44th Annual J.P. Morgan Healthcare Conference

PLEASANTON, Calif., Dec. 29, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell…

1 hour ago

Tri-City Cardiology’s Ambulatory Surgical Center Surpasses 6,000 Procedures, Marking a Major Milestone in Outpatient Cardiovascular Care

MESA, Ariz., Dec. 29, 2025 /PRNewswire/ -- Tri-City Cardiology's Ambulatory Surgical Center (ASC), legally referred to…

1 hour ago

LG NOVA UNVEILS NEXT GENERATION OF AI-FIRST VENTURES AT CES 2026

Collaborative AI-First Ventures Delivers Impactful Solutions for Health, Energy, Small Business and Enterprise SectorsLAS VEGAS,…

1 hour ago

Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon…

1 hour ago

Through High-Profile Ambassadors and Major Partnerships, ZetrOZ Systems Expanded Reach of sam Device in 2025

The leader in sports medicine healing innovations worked with athletes, athletic trainers, physicians and foundations…

4 hours ago